These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 36422708)
1. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study. Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708 [TBL] [Abstract][Full Text] [Related]
2. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study. Areskog Lejbman I; Torisson G; Resman F; Sjövall F Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447 [TBL] [Abstract][Full Text] [Related]
3. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion. Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189 [TBL] [Abstract][Full Text] [Related]
5. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients. Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860 [TBL] [Abstract][Full Text] [Related]
6. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974 [TBL] [Abstract][Full Text] [Related]
9. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections. Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1). Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376 [TBL] [Abstract][Full Text] [Related]
11. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA; J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783 [TBL] [Abstract][Full Text] [Related]
12. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759 [TBL] [Abstract][Full Text] [Related]
13. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal. Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492 [TBL] [Abstract][Full Text] [Related]
14. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients. Landmesser KB; Clark JA; Burgess DS J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542 [TBL] [Abstract][Full Text] [Related]
15. Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children. Tang Girdwood SC; Tang PH; Murphy ME; Chamberlain AR; Benken LA; Jones RL; Stoneman EM; Kaplan JM; Vinks AA J Clin Pharmacol; 2021 Apr; 61(4):565-573. PubMed ID: 33111331 [TBL] [Abstract][Full Text] [Related]
16. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706 [TBL] [Abstract][Full Text] [Related]
17. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP. Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972 [TBL] [Abstract][Full Text] [Related]
18. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]